GreenLight Biosciences Holdings, PBC
GreenLight Biosciences Holdings, PBC (GRNA): 7 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.4 months
D/E 4.18 · 0% dilution
Lead: Phase 1
7 candidates
N/A
N/A
A transparent, data-derived signal for GreenLight Biosciences Holdings, PBCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$33.8M
Quarterly Burn
$31.1M
Runway
3.4 mo
Revenue
$3.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| calantha | Preclinical |
| covid-19 vaccine | Preclinical |
| glb-cov2-043 | Phase 1 |
| personalized cancer vaccine | Preclinical |
| seasonal flu vaccine | Preclinical |
| sickle cell disease product | Preclinical |
| varroa mite | Preclinical |
Frequently asked questions
How many drug candidates are in GreenLight Biosciences Holdings, PBC's pipeline?
GreenLight Biosciences Holdings, PBC (GRNA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GreenLight Biosciences Holdings, PBC's lead drug candidate?
GreenLight Biosciences Holdings, PBC's most advanced tracked candidate is calantha (Preclinical) for Colorado potato beetle.
What is GreenLight Biosciences Holdings, PBC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GreenLight Biosciences Holdings, PBC has approximately 3.4 months of cash runway.
Get the full picture on GreenLight Biosciences Holdings, PBC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.